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1. Introduction 
Drug development is time- and cost-intensive and, overall, inefficient. Only one out of an 
estimated 10.000 new chemical entities (NCEs) finally enters the market. The later the failure 
occurs, the higher are the costs. It is for this reason that preclinical development aims at 
identifying the potential for failure as early as possible and with high sensitivity. On the 
other hand, high sensitivity generally also means low specificity, suggesting that many 
potentially successful NCEs are currently excluded from further development. Common 
reasons for exclusion are adverse drug reactions (ADR). Among the various ADRs, cardiac 
toxicities and arrhythmias play an important role, because they represent about 21% of all 
ADRs (Lasser et al., 2002) and are frequently lethal. The single most important mechanism 
in this context is the prolongation of cardiac repolarization bearing a proarrhythmic 
potential. These interferences can be visualized by standard ECGs as a prolongation of the 
QT-interval. Such a prolongation is called “long QT-syndrome” (LQT-syndrome) and is 
associated with Torsade-de-Pointes (TdP) arrhythmias and sudden cardiac death. In the past, 
several prominent drugs had to be withdrawn from the market due to TdP in humans, e.g. 
astemizole, terfenadine, cisapride, sparfloxacin, grepafloxacin and recently clobutinol 
(Silomat). Moreover, numerous drugs are still on the market that are associated with the 
potential to cause LQT and TdP, including widely prescribed drugs such as the antibiotic 
erythromycin.  
Given the fatal consequences of LQT and TdP in healthy patients without any cardiac 
disposition, the regulatory bodies (FDA, EMEA and others) have decided some years ago to 
require testing for LQT to be an obligatory part of preclinical development of any NCE. 
Several tests have been developed and some of them are routinely used. The three major 
(but by far not exclusive) tests in the field are the HERG test, rabbit Purkinje fibers and 
telemetry in dogs. These tests have different advantages and disadvantages and are 
generally employed subsequently. The HERG test can be considered an obligatory test for 
all NCEs and it is unlikely that any company further develops a compound that showed 
major inhibitory activity in this test (of a single ion channel activity). However, examples 
exist of successful drugs on the market that are potent inhibitors of the HERG current 
without ever giving rise to TdP arrhythmia (e.g. verapamil, azithromycin). Thus, the 
predictive value of the HERG test is limited. Reasons lie, among others, in its inability to 
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give an integrated readout of effects of drugs on the electrophysiology of the intact cardiac 
myocyte or the intact heart as a multicellular organ consisting of a functional syncytium of 
cardiac myocytes and all other cardiac cell types that make up normal heart tissue (e.g. 
fibroblasts, endothelial cells and smooth muscle cells). 
1.1 Cardiac tissue engineering 
Over the past decade, techniques have been developed to generate cardiac tissue-like 3-
dimensional constructs in vitro (Eschenhagen & Zimmermann, 2005). The field of cardiac 
tissue engineering opened the possibility for many applications. Artificial hart constructs 
may serve as means for cell-based cardiac repair and as improved in vitro models for 
predictive toxicology and target validation, taking advantage of a more physiological 
cellular environment. Previous studies used different approaches to construct engineered 
tissues: Cell seeding onto solid, preformed scaffolds (Carrier et al., 1999; Engelmayr et al., 
2008; Leor et al., 2000; Li et al., 2000; Ott et al., 2008; Radisic et al., 2004), matrix-free 
generation of tissues from stackable cell sheets (Shimizu et al., 2002) or the generation of 
constructs in preformed casting moulds using hydrogels such as collagen I, matrigel, 
fibronectin or fibrin (Bian et al., 2009; Eschenhagen et al., 1997; Huang et al., 2007; Naito et 
al., 2006; Zimmermann et al., 2002). The hydrogel technique has been shown to be suitable 
for both, cardiac repair in vivo (Zimmermann et al., 2006) and target validation in vitro (El-
Armouche et al., 2007). Circular engineered heart tissues (EHTs) were made by casting 
neonatal rat heart cells, collagen I and matrigel into circular casting moulds and develop a 
high degree of cellular differentiation, longitudinal orientation, intercellular coupling and 
force generation (Zimmerman et al., 2002). It turned out that several factors improve tissue 
quality and force generation of EHT such as phasic (Fink et al., 2000) or auxotonic stretch, 
increased ambient oxygen concentration during culture and supplementation with insulin 
(Zimmermann et al., 2006). Others demonstrated beneficial effects of electrical stimulation 
(Radisic et al., 2004). The possibility to generate cardiac myocytes from human embryonic 
stem cells (Kehat et al., 2001) or induced pluripotent stem cells (Zhang et al., 2009) have 
opened the realistic and exciting perspective to use these techniques for the validation of 
hypotheses and testing drugs in healthy and diseased human heart muscles (Zimmermann 
& Eschenhagen 2007). 
The current techniques to generate engineered cardiac tissues are either not suitable for this 
purpose (stacked cell sheet technique) or exhibit drawbacks that limit their usefulness. 
Extensive handling steps preclude routine execution of large series in an at least medium 
through put scale and are always a source of variability. Furthermore, the EHT technique in 
the ring format requires relatively high numbers of cells and turned out to be difficult to 
miniaturize. 
In this chapter we describe a new EHT technique that was driven by the intention to 
miniaturize the EHT-format for multi-well-testing and automated evaluation and to 
determine the suitability of EHTs for drug screening and predictive toxicology. The main 
results have been published in a recent original paper (Hansen et al. 2010). An essentiel 
change was to use fibrin(ogen) instead of collagen I as a matrix. Fibrinogen is part of the 
blood clotting cascade. It is a glycoprotein with a size of 340 kDa. Physiologically it achieves 
plasma concentrations of 1.5 to 4 g/l and can be relative easily purified from different 
species. An important mechanical property is its nonlinear elasticity. Due to this, fibrin 
polymers have a high elastic modulus under shear stress combined with a beneficial 
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softness in comparison to other filamentous biopolymers (Janmey et al., 2009). The final 
properties of fibrin are mainly governed by the concentrations of fibrinogen and thrombin. 
Additionally fibrin properties can be affected by the introduction of bonds by plasma 
transglutaminase (factor XIII; Janmey et al., 2009). In contrast to other extracellular matrices, 
the in vitro polymerisation of fibrin is very close to the in vivo fibrin polymer. Fibrin gels are 
fully degradable by fibrinolytic enzymes like plasmin. All together, the mechanical and 
biological properties, its availability from autologous sources in addition to the possibility to 
covalently bind growth or other factors (Hubbell 2003) make fibrin an interesting compound 
for tissue engineering approaches. 
2. Methods 
2.1 Cell isolation 
Total heart cells (excluding the atria) were isolated from neonatal Wistar rats (postnatal day 
0 to 3) by a fractionated DNase/Trypsin digestion protocol as previously described 
(Eschenhagen & Zimmermann, 2005). The resulting cell populations were immediately 
subjected to FBME generation. Experimental procedures were reviewed and approved by 
Ethics Committee, Hamburg University. 
2.2 Manufacturing teflon spacers and sylgard posts racks 
For the generation of fibrin-based mini-EHTs (FBMEs), Teflon spacer and silicone post racks 
were used. The Teflon spacers were important for the casting molds. They had the following 
geometry (Figure: 1B): length 12 mm, width 3 mm, height 13.5 mm. Sylgard 184 silicone 
elastomer (Dow Corning) was used for the production of silicone post racks, which were 
needed for culturing the FBMEs. The silicone post racks were made in custom-made Teflon 
casting molds. According to the manufacture’s instructions, the 2-component Sylgard 184 was 
degassed under vacuum conditions before casting. The final silicone post racks consisted of 4 
pairs of posts, having a little plate at their end. The racks had the following geometry (Figure 
1A): length/width of rack: 79x18.5 mm, length of posts 12 mm, diameter 1 mm, plate diameter 
2 mm, distance (center-center) 8.5 mm. They were initially self-made and currently industrial-
made. Silicone post racks can be autoclaved and reused for several times. 
2.3 Generation of fibrin-based mini-EHTs 
The reconstitution mixture for the generation of fibrin-based mini-EHTs was prepared on 
ice as follows (final concentration): 4.1x106 cells/ml, 5 mg/ml bovine fibrinogen (Sigma 
F4753, stock solution: 200 mg/ml in 0.9% NaCl supplemented with 0.5 µg/mg aprotinin), 
3 U/ml bovine thrombin (Sigma T7513, stock solution: 100 U/ml). To ensure isotonic 
conditions, one additional fibrinogen and thrombin volume of 2x DMEM was added. 
Ordinary 24-well cell culture plates were used as casting molds. After 1.6 ml of sterile 2% 
agarose (Invitrogen 15510-027) in PBS was pipetted into each well, the Teflon spacers could 
be placed. After the agarose was solidified, the Teflon spacers were removed. The silicone 
posts racks were placed onto the cell culture dish with each pair of silicone posts reaching 
into one of the preformed casting molds (geometry: 12x3x4 mm). The reconstitution mix was 
carefully resuspended. For each FBME 100 µl of the mixture was mixed briefly with an 
appropriate volume of thrombin and pipetted into an agarose slot. To ensure complete 
polymerization of the fibrinogen, the constructs were placed into a humidified cell culture 
incubator (37 °C, 7% CO2, 40% O2) for 2 hours. Before transferring the silicone posts racks to 
www.intechopen.com
 Toxicity and Drug Testing 74
a new medium-filled culture plate, every construct was covered with DMEM (300 µl) to ease 
the removal. FBMEs were maintained in 37 °C, 7% CO2, 40% O2 in a humidified cell culture 
incubator. Media was changed on Mondays, Wednesdays and Fridays. FBME medium 
consisted of DMEM (Biochrom F0415) supplemented with 10% horse serum (Gibco 26050), 
2% chick embryo extract (self-made), 1% penicillin/streptomycin (Gibco 15140), insulin 
(Sigma I9278, 10 µg/ml) and aprotinin (Sigma A1153, 33 µg/ml). 
 
 
Fig. 1. Illustration of the experimental setup for casting and cultivation and photography of a 
silicone post rack with four FBMEs. Silicone post rack with four FBMEs (turned upside down, 
scale in millimetres; A). Teflon spacer for the generation of agarose casting molds (turned 
upside down, scale in millimetres; B). Illustration of FBME generation (C). First lane: Casting 
molds are made using Teflon spacers and agarose in a 24-well cell culture dish. Silicone posts 
racks are placed onto the culture dish, with each pair of posts reaching into a mold. Second 
lane: Mastermix is pipetted into each mold. Third lane: After 2 h the fibrin is polymerized and 
the silicone posts are embedded in the hydrogel. FBMEs can be transferred into a new 
medium-filled 24-well culture plate. Fourth lane: FBMEs are maintained in culture for 15 to 30 
days (Hansen et al. 2010). 
2.4 Video-optical analyses 
The setup for video-optical analyses consisted of a cell culture incubator-like unit, in which 
gas conditions, humidity and temperature could be controlled. This device was equipped 
with a glass roof for monitoring purposes. A Basler CCD-camera (Type A 602f-2) was 
attached to an XYZ-device (IAI Corporation) and positioned above the glassroof in a PC-
controlled manner. Light-emitting diodes (LEDs) were placed underneath the cell culture 
dish. Illumination of a single LED was synchronized with the video-optical recording 
procedure in order to minimize heating of the cell culture medium by LED waste heat. 
Figure 2A shows a schematic picture of the whole setup and 2B shows a 24 well cell culture 
plate with six silicone posts racks and with one FBME in every well (view from above). For 
the video-optical analyses a customized software package developed by Consulting Team 
Machine Vision (ctmv.de; Pforzheim, Germany) was used. This software is based on figure 
recognition and is able to identify the FBME’s shape in a fully automated manner. In brief, 
the system automatically places measuring points at the top and bottom end of the 
contracting muscle strip. Due to the contraction, the distance in between the moving silicone 
posts changes. These changes are determined and recorded by the software over time. Based 
on post geometry, elastic modulus of the Sylgard 184 (2.6 kPa) and the delta value of post 
distance (post deflection), the developed force was calculated based on a recently published 
A 
B 
C 
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equation (Vandenburgh et al. 2008). The recorded contractions are filtered and identified as 
such by certain peak criteria (e.g. threshold value, minimal force and minimum relaxation). 
Besides average force, the software calculates values for frequency, fractional shortening, 
contraction- and relaxation time (bpm, T1 and T2, respectively) based on the recognized 
contraction peaks. T1 and T2 were determined at 20% of peak maximum. Reports with an 
overview of the environmental information (temperature, gas, humidity) in the cell culture 
like unit plus all calculated parameters are automatically generated after each run. These 
underlie two levels of quality control: pictures are taken at the beginning and the end of 
each recording. Blue squares indicate top and bottom end of each respective FBME where 
the software placed the points for the measurement (Figure 2D). Contractions are recorded 
as force development over time. Identified peaks, which are included in the calculation, are 
marked with green squares (Figure 2C). The effort to analyse a 24-well plate with 
contracting muscle strips is limited to defining the XYZ-coordinates for each well once 
before starting a series of measurements. 
 
 
 
Fig. 2. Illustration of the experimental setup for video-optical recordings of FBME, a 24 well 
cell culture dish with FBMEs, a magnified view of a single FBME as recorded by the video 
camera and an example of a contraction pattern (one FBME for 60 s). A shows a schematic 
picture of the experimental setup for video-optical recordings. In B a 24 well cell culture 
dish with FBMEs is shown (view from above). The original contraction pattern of one FBME 
over time (60 s, C). Image of a contractile muscle strip from an automatically generated 
report (D). Blue squares indicate positions automatically recognized by the software at top 
and bottom end of the FBME. Green squares mark the recognized contraction peaks which 
are included for the calculation of several parameters (Hansen et al. 2010). 
B 
D 
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3. Results 
3.1 General aspects of the new technique 
We developed a new technique for the generation and evaluation of contractile cardiac 
tissue from neonatal rat heart cells in vitro (Hansen et al. 2010). In this method, isolated heart 
cells are mixed with fibrinogen, thrombin and medium and pipetted into rectangular casting 
moulds made from 2%-agarose in ordinary 24-well cell culture plates. Due to the 
polymerisation of the fibrin, the gel is fixed to both silicone posts. After 2 h at 37 °C the 
constructs can be transferred to new culture dishes and maintained under cell culture 
conditions for several days. Figure 1C demonstrates this procedure in a schematic way. 
During cultivation, the cells inside the gel spread along the force lines and form extensive 
cell-cell contacts, the hydrogel is remodelled and degraded. These processes are 
accompanied by marked condensation of the constructs and deflection of the silicone posts 
towards each other. The initial length of a FBME directly after casting is 8.5 mm and the 
mean final length 6.5 mm. The post deflection differs between individual FBMEs, likely 
reflecting their degree of cardiac tissue development. In consequence, each FBME is exposed 
to an “individually optimized preload”. With this simplified method, 48-72 FBMEs can be 
routinely generated out of one cell preparation (30 rat hearts). Figure 2B illustrates a typical 
24 well plate with silicone posts racks and FBMEs. Fibrin is affected by proteases in the 
culture medium. To decrease degradation, the protease inhibitor aprotinin at a 
concentration of 33 µg/ml is added to the medium. This inhibitor markedly reduces 
fibrinolysis but cannot entirely stop it. To further protect the hydrogel from proteolysis 
tranexamic acid, another protease inhibitor, can be added to the medium. The combination 
of both inhibitors results in improved stability and allows longer cultivation periods. 
Tranexamic acid-treated FBMEs have a markedly increased diameter (final width 1.3 to 
1.4 mm [Figure 2C and 8D] instead of 0.2 to 1.0 mm in its absence [Figure 4A]). 
3.2 Morphology and beating activity 
Directly after casting, FBMEs appeared as a soft fibrin-block fixed at the end of the 
silicone posts and exhibiting the dimensions of the casting moulds (12x3xx mm). Within 
this clot, the heart cells were round and amorphous but homogeneously distributed 
throughout the gel (Figure 3A). During the first days after casting, cells spread, elongated 
along force lines, started to beat as single cells and finally in the form of synchronously 
beating areas on day 4 to 5. The further development was characterized by matrix 
remodelling and degradation. This lead to a marked reduction of the size (from 3 mm to 
1-2 mm width in the presence and 0.2-1 mm in the absence of tranexamic acid) and 
increased cell-density. Between day 5 and day 7 the cardiomyocytes formed small groups 
(Figure 3B through E). Coherent beating of the muscle construct started around day 7 to 9. 
By day 10 the generated force was sufficient to rhythmically deflect the silicone posts. 
Measurements were routinely performed between day 14 to 16. At this point the 
cardiomyocytes finally appeared as spindle-shaped cells with an approximately length of 
100 to 200 µm and a diameter of 10 to 20 µm (Figure 3F). 
Hematoxylin/eosin-stained paraffin sections of mature FBMEs (day 15) showed a dense 
network of longitudinally aligned cells throughout the gel (Figure 4A). No clear evidence for 
cell density gradient from peripheral to central areas of the gel could be found, arguing 
against a significant inhomogeneity of oxygen and nutrient supply. 
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Fig. 3. Histological analysis of FBMEs. FBMEs were cultured with aprotinin plus tranexamic 
acid. For histological analysis they were fixed with formaldehyde at indicated time points, 
embedded with paraffin and the sections were HE-stained (10x magnification). A Day 0: 
cells are present as single, round and amorphous cell suspension in fibrin matrix; B day 3: 
cells spread out along force lines. C day 6, D day 9: degradation of extracellular matrix, cells 
spread and align with neighbouring cells. E day 12, F day 15: extended degradation of 
extracellular matrix, the cellular density is increased; cells align and show orientation along 
force lines. Scale bar 100 µm (Hansen et al. 2010). 
Whole-mount FBMEs were also analysed by immunofluorescent staining. The pictures 
showed a dense network of regularly cross striated, ǂ-actinin-positive, longitudinally 
aligned cardiomyocytes. The elongated cells had well developed sarcomeric structures 
reaching into the periphery of the cytoplasm. Cardiomyocytes were also characterized by 
connexion-43 positive structures, the gap junctions. In contrast to the in vivo situation 
connexion-positivity was mostly localized on lateral parts of the cell membrane, but not 
clustered at the border to connecting cells. Moreover, the immunfluorescence showed lectin-
positive endothelial cells intermingled with cardiomycytes and forming primitive tube-like 
structures (Figure 4). 
E 
C 
F 
D 
B A 
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Fig. 4. Histological analysis of FBMEs (day 15, without tranexamic acid). A, HE-stained 
paraffin section. Note the almost complete absence of extracellular matrix and well-
developed cardiac tissue structure. B, Merged immunofluorescence staining for ǂ-actinin 
(green), lectin (red) and DRAQ5 (blue; 63x magnification). C, Lectin-positive structures 
alone (63x magnification). D, Connexin-43 (red), phalloidin (green) and DRAQ5 (blue; 63x 
magnification). Scale bar 50 µm (A) and 20 µM (B-D; Hansen et al. 2010). 
3.3 DNA/RNA content, histone H3 phosphorylation and caspase-3 activity 
To further investigate cell survival in FBMEs during culture, the histological data were 
supported by measurements on a molecular biological level. The DNA/RNA content, 
histone H3 phosphorylation as well as the caspase-3-activity were analysed. The DNA 
content dropped by 20% between day 0 and day 3. Thereafter it remained stable for at least 
two weeks (Figure 5A). Investigations of histone H3 phosphorylation as a marker of 
proliferative activity and caspase-3 activity as a marker for apoptosis in FBMEs were well in 
line with these observations. Histone H3 phosphorylation level was initially very low and 
further decreased over time (Figure 5C). Caspase-3 activity was high directly after cell 
preparation and dropped during culture even below detectable levels (Figure 5D). After an 
initial drop of the RNA-content during the first three days of 50% it remained, like the DNA 
content, more or less stable for at least two weeks (Figure 5B). In summary, these data 
suggest that some of the cells died within the first three days after casting, likely as a 
consequence of cell damage during the isolation procedure. Thereafter the cell population 
remained essentially stable in FBMEs. 
D 
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Fig. 5. DNA and total RNA content of FBMEs. A DNA content of FBMEs over time (n=4). B 
Total RNA content over time (n=4). * p<0.05 vs. d0 (Student’s t test). Bars show means +/- 
SD. C, D Concentration of phosphorylated histone H3 (C) and caspase-3 activity (D) in 
FBMEs over time of cultivation. Day 0 represents freshly solidified FBMEs 2 h after casting. 
Proliferating HEK293 cells and AraC-treated FBMEs served as positive and negative 
controls for proliferation, respectively. Doxorubicin-treated FBMEs served as positive 
controls for caspase-3 activity. Bars show mean +/-SEM, n=4. * p<0.05 vs. d0 (Student’s t 
test; Hansen et al. 2010). 
3.4 Cardiac marker gene expression over time 
To get an idea about cardiomyocyte maturation in FBMEs, transcript levels of known 
cardiac marker genes (ǂ-actinin, SR Ca2+-ATPase [SERCA], ǂ- and ǃ-myosin heavy chain 
[ǂ-/ǃ-MHC], Na+/Ca2+-exchanger [NCX], titin) were analysed over time. To avoid bias 
due to the effect of the drop of overall cell count after preparation, all values were 
normalized to the mRNA concentration of the cardiac myocyte-specific protein 
calsequestrin 2. Values were additionally compared to intact adult (ARH) and neonatal rat 
hearts (NRHT; Figure 6). In the first phase (day 0 to day 6), which represents the time 
when the single cells spread, formed clusters and started to beat, the transcript levels 
seemed to be relatively stable. In the second phase (day 9 to day 12) the expression levels 
reached their maximum concomitantly with the start of rhythmical deflection of the 
silicone posts by the FBMEs. In the third phase (day 12 to day 15) transcript levels 
generally decreased. Some cardiac markers (ǂ-actinin, SERCA, ǂ-MHC) reached a 
comparable level to native myocardium on day 15. Other (ǃ-MHC, titin and NCX) 
remained several fold higher, indicating higher remodelling activity. 
A 
C 
B 
D 
www.intechopen.com
 Toxicity and Drug Testing 80
 
 
Fig. 6. RT-qPCR of FBMEs in comparison to neonatal (NRHT) and adult rat heart (ART). 
∆∆CT values were generated by normalisation to the mRNA of cardiac specific protein 
calsequestrin 2 (average CT values for normalisation were as follows: d0: 20.8, d3: 20.4, d6: 
20.6, d9: 21.3, d12: 21.6, d15: 20.5). Figures show relative expression compared to day 0. Each 
bar represents results from 4 biological replicates (each measured 3 times). * p<0.05 vs. 
day 15 (Student’s t test). Bars show means +/- SEM (Hansen et al. 2010). 
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3.5 Non quantitative ion channel expression profile 
Ion channels play an important role as targets of proarrhythmic drugs. To determine 
whether the principal ion channel subunits known from human hearts are expressed in rat 
FBMEs transcripts of 23 ion channel ǂ-subunits (7 calcium channels, 6 sodium channels, 10 
potassium channels) were amplified from total RNA of FBMEs and a nonfailing human 
heart sample by RT-PCR (35 cycles). 22/23 transcripts were amplified from both sources, 
one channel (CacnA1I) was neither amplified in FBMEs nor in the nonfailing human heart 
(Figure 7).  
 
 
Fig. 7. Agarose gel of the PCR-products of 23 ion channel subunits. The ion channel profile 
of FBMEs was compared to the expression profile of a nonfailing human heart. Potassium 
channels (A), calcium channel (B) and sodium channels (C) showed qualitatively similar 
results (descriptions indicate the related gene for each channel subunit; for further 
information see table 1; Hansen et al. 2010). 
3.6 Robustness and reproducibility of the new method 
To determine robustness and reproducibility or the assay, we generated 6 independent 
series of FBMEs (1-2 24-well plates each, total number 192 FBMEs) and analysed them under 
standard conditions (culture medium with insulin, aprotinin and tranexamic acid; 
measurements done by video-optical recordings). Two FBMEs could not be transferred from 
the casting moulds, 4 FBMEs were not recognized by the software and 17 did not beat 
during the recording time (60 s) at day 15. Thus, the total success rate was 89% (169/192; 
Figure 8). Contraction parameters were examined and compared among different series. 
These results showed that the average force per series (day 15) was between 0.11 and 
0.22 mN (series SD 7.6%), the contraction time (T1=time to peak) ranged between 66 and 
81 ms (series SD 41%), relaxation time (T2=time to 80% relaxation) between 67 and 88 ms 
(series SD 25%), frequency between 162 and 20 beats per minute (series SD 109%), construct 
diameter between 1.3 and 1.4 mm (series SD 9.9%) and length between 5.6 and 6.7 mm 
(series SD 16.7%). The relatively large size in FBME diameter in these examinations could be 
attributed to the use of tranexamic acid. 
B 
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Family Abbre-
viation 
Description 
KCN A5 Voltage-gated channel subunit Kv1.5 
D3 Voltage-gated channel subunit Kv4.3 
E1 Potential voltage-gated channel subunit beta  
(KvLQT1; ERG; function: IKs or Kr) 
E2 Potential voltage-gated channel subunit beta  
(minK-related peptide 1; KvLQT1; ERG; function: IKs or IKr) 
H2a IKr producing rapid voltage-gated channel subunit beta  
(ether-a-go-go-related gene (ERG) channel 1) 
J3 G protein-activated inward rectifier channel 1 (Kir3.1) 
J5 G protein-activated inward rectifier channel 4 (Kir3.4) 
J8 ATP-sensitive inward rectifier channel 8 (Kir6.1) 
J12 ATP-sensitive inward rectifier channel 12 (Kir2.2) 
Q1a IKs producing slow voltage-gated channel subunit alpha (KvLQT1) 
CACN A1C Voltage-dependent subunit alpha-1C (L-type) 
A1H Voltage-dependent subunit alpha-1H (T-type) 
A1I Voltage-dependent subunit alpha-1I (T-type) 
B1 Voltage-dependent subunit beta-1 (L-type) 
B2 Voltage-dependent subunit beta-2 (L-type) 
B3 Voltage-dependent subunit beta-3 (L-type) 
B4 Voltage-dependent subunit beta-4 (L-type) 
SCN 1A Voltage-gated channel protein type-1 subunit alpha 
3A Voltage-gated channel protein type-3 subunit alpha 
1B Voltage-gated channel subunit beta-1 
4A Voltage-gated channel protein type 4 subunit alpha 
4B Voltage-gated channel subunit beta-4 
5A Voltage-gated channel protein type-5 subunit alpha 
Table 1. Overview of the analysed ion channels shown in figure 7. 
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Fig. 8. Reproducibility of the assay. FBMEs were generated at 6 different time points 
(series 1-6) and spontaneous activity was recorded on day 15. Parameters of contractility (A: 
force, B: frequency, C: contraction time T1, relaxation time T2) and construct dimensions (D) 
were averaged and compared. Minimal and maximal values were used to test for significant 
differences and are indicated with * p<0.05 (Student’s t test). Bars show means +/- SD. 
Analysed FBMEs for each series were: Series 1: n=21, series 2: n=24, series 3: n=20, series 4: 
n=18, series 5: n=39, series 6: n=47 (Hansen et al. 2010). 
3.7 Cardiotoxic and proarrhythmic effects of drugs 
To determine whether the new method could be used for the detection of cardiotoxic and 
proarrhythmic drug effects, well characterized compounds with known cardiotoxic and 
repolarization-inhibitory effects were tested. The cardiotoxic drug doxorubicin was applied 
in different concentrations (0.1-1.000 nmol/L) for up to 96 h. Doxorubicin-treated FBMEs 
showed time- and concentration-dependent changes in contractile force. Very low 
concentrations of doxorubicin (1-10 nmol/L) led to a trend towards an increase in contractile 
force, 100 nmol/L induced a transient increase in contractile force after 24 h which was 
followed by a decrease at 72 and 96 h (Figure 9). In the presence of 1 µmol/L doxorubicin all 
FBMEs stopped to beat after 3 days. 
To examine a repolarization-inhibitory effect on FBMEs, the experimental IKs-blocker 
chromanol 293B as well as the clinically used drugs quinidine and erythromycin were  
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Fig. 9. Doxorubicin toxicity on FBMEs. FBMEs were incubated in the presence of doxorubicin 
(0.1-1000 nM, starting at day 13 of culture), average forces were determined daily. While 
doxorubicin at 0.1 µM increased force after 24 hours, higher concentrations (1 µM) lead to a 
time-dependent reduction in force development. * p<0.05 (Student’s t test). Bars show means
+/- SEM, number of evaluated (beating) constructs as indicated (Hansen et al. 2010). 
tested. All three compounds induced a concentration-dependent delay in relaxation time 
(T2; Figure 10). In the presence of chromanol 293B, FBMEs already showed a prolongation 
of T2 at a concentration of 1 µmol/L. At 100 µmol/L chromanol, T2 was 7-fold longer than 
control, resulting in a “church-like” configuration of the twith (Figure 10). Quinidine and 
erythromycin, both associated with arrhythmias in clinical applications, also extended the 
relaxation time at high concentrations (100 µmol/L). Time of contraction was not affected by 
any of the compounds. 
 
 
Fig. 10. Chromanol 293B-induced “church-like” contraction pattern. Cutout of the original 
contraction recordings in the presence and absence of Chromanol 293B (100 µM; modified 
from: Hansen et al. 2010). 
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Fig. 11. Effect of repolarisation inhibitors on FBME contraction (T1) and relaxation time (T2). 
FBMEs were incubated with increasing concentrations of the indicated compounds (1-2 h) 
and evaluated before application of drug (baseline) and after each concentration. Note the 
absence of effect of all compounds on T1 and the concentration-dependent increase in T2 
with chromanol, quinidine and erythromycin (at 1000 µM of erythromycin FBMEs 
discontinued contractile activity). A typical alteration of contraction peak morphology with 
increasing concentrations of quinidine, chromanol and erythromycin is shown in 
supplementary figure 5. * p<0.05 (Student’s t test). Bars show means +/- SEM, each spot 
represents one analysed FBME (Hansen et al. 2010). 
4. Conclusion 
In this book chapter we describe a recently developed method (Hansen et al. 2010) to 
generate miniaturized, fibrin-based EHTs (FBMEs) in a 24-well format and determine their 
contractile activity in an automated manner. This technique turned out to be robust and 
highly reproducible. Its main advantages are its simplicity in terms of handling, the 
standard 24-well format, its robustness and the high content automated readout of 
contractile activity. Compared to previously EHT-protocols (Eschenhagen et al. 1997, 
Zimmermann et al. 2002), three major changes were introduced. (i) Collagen I was replaced 
by fibrinogen and thrombin. Due to the fast fibrin-polymerisation, the heart cells were 
homogenously distributed throughout the entire hydrogel. Polymerisation occurs in 
minutes and allows transfer of the constructs from the casting moulds to a new medium-
filled culture dish after two hours. Moreover, fast solidification allowed 50% higher cell 
concentration (0.6x106/150 µl versus 2.5x106/900 µl), because it prevents accumulation of 
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cells at the bottom of the casting moulds with detrimental consequences. Fibrin has 
additional advantages for future applications, such as transplantations. It is available from 
autologoues sources and has the ability to couple covalently growth-promoting, angiogenic 
or other interesting factors (Hubble 2003). (ii) The original ring-format was changed to a 
stripe-format. This step was very important because it allowed miniaturization (volume 
reduced from 900 to 150 µl), the use of standard 24-well plates and automation. The silicone 
racks with 4 pairs of posts each allow simple transfer of FBMEs from one plate to another 
and thus reduce the number of nonstandardized handling steps to a minimum. Moreover, 
the silicone posts subject the growing muscle construct to an individually optimized preload 
and allow them to perform contractile work against the elastic properties of the post. (iii) 
Video-optical measurements of contractile parameters further improved the whole 
technique. They superseded the manual transfer for measurements as it was required in 
former EHT-protocols. Additionally, video-optical recordings allowed simple, reproducible, 
standardized measurements of large series in a short spell. 
The new stripe-format was inspired by a previously described method for generating 
skeletal muscle tissues (Vandenburgh et al. 2008). Turning the silicone posts up side down 
was the major difference to this method and simplified handling. In this way the quality of 
the constructs could be determine with an ordinary microscope or even by eye and opened 
the possibility for automated video-optical recordings from above the plate. This 
experimental setup, in combination with fibrin, has several important features. (i) It is 
simple and not longer addicted to some kind of special dish because standard 24-well cell 
culture plates can be used. In the beginning silicone posts racks were self-made, which 
turned out to relevantly limit reproducibility. We therefore have the racks industrial made 
now, which makes the method robust and highly reproducible (Figure 8). (ii) FBMEs exhibit 
an excellent cardiac tissue development (Figure 4). Several factors are likely to contribute to 
these beneficial effects. As outlined above, the fast polymerisation of fibrin allowed higher 
cell concentrations and lead to homogenous cell distribution throughout the hydrogel. 
Another reason was that cell survival appeared very high in the current fibrin-based format. 
Moreover, proliferative activity (of non-myocytes) was very low (Figure 5), making the 
system stable over prolonged periods. The stable mRNA expression pattern of cardiac 
markers (ǂ-actinin, ǂ-MHC, titin, calsequestrin 2 and SERCA) may be an additional hint for 
a relatively stable system. Interestingly, the fetal gene marker ǃ-MHC showed a several fold 
decrease within in the first six days. This phase was associated with cell spreading and 
contractions on a cellular level. Later, between day 6 and day 9 there was a ~5-fold increase 
of the ǃ-MHC mRNA expression, coinciding with the beginning of macroscopic 
contractions. A third positive effect of the described new technique is the optimized 
mechanical load on the cardiomyocytes. The mechanical load is produced by the resistance 
of the silicon posts and adapted individually for each FBME. If the tonic (diastolic force) of 
the construct is high, post deflection by the FBMEs is stronger and vice versa. Furthermore, 
the FBMEs can perform contractile work against an elastic resistance. These circumstances 
mimic in some ways the in vivo situation in which the beating heart needs to work against 
the afterload induced by the total peripheric resistance. This kind of optimized “auxotonic” 
load in contrast to motorized phasic stretch improves tissue development as shown earlier 
in other EHT-studies (Zimmermann et al. 2006).  
Regarding the development of a drug screening, miniaturization, reduction of 
nonstandardized steps during the procedure and an automated, objective readout were very 
important. The miniaturization to a 24-well format reduced the cell number by a factor of 
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~4. Additionally, pilot experiments could show that a further miniaturization to a 96-well 
format would be possible. At this point the 24-well format turned out to be a good 
compromise between miniaturization and ease of handling. FBMEs do not longer need to be 
manually transferred as single tissues because the entire silicon racks were handled. In 
contrast to that, circular EHTs needed to be manually transferred from the casting mould to 
a motorized stretcher and finally from the stretcher to the organ bath for the measurements. 
Compared to this method, the video-optical recordings were simple and robust. To confirm 
the calculated forces, isometric measurements were exemplarily done in the organ bath in 
parallel and showed that the calculated forces were roughly in the range of the measured 
ones (0.3 vs. 0.9 mN). The threefold difference could indicate a systematic error, but more 
likely reflects optimized conditions in the organ bath (preload optimization, electrical 
pacing and isometric versus auxotonic contraction). A force of 0.9 mN (organ bath) and a 
diameter of 0.2 mm (Figure 4A; without tranexamic acid) results in a relative force 
development of 28.7 mN/mm2. This is still lower than values in an intact muscle 
(50 mN/mm2), but point in the right direction. The development of a software which works 
by automated figure recognition was important in two aspects. On the one hand, it is time-
saving since it calculates all important contractile parameters automatically. On the other 
hand, it provides an objective readout. 
Initial experiments to determine the suitability of FBMEs to detect either cardiotoxic or 
proarrhythmic effects looked promising. The known cardiotoxic drug doxorubicin 
suppressed contractile activity at the highest concentration (1.000 nmol/L) and increased 
force at lower concentrations (100 nmol/L) and earlier time points (24 h). This may be due to 
the reactive oxygen species-generating effect of this compound, which at later time points 
and/or higher concentrations turned into toxicity.  
Three known proarrhythmic drugs caused a concentration-dependent prolongation of 
relaxation time in FBMEs. Chromanol 293B is an experimental IKs-blocker with an IC50-value 
of 8 µmol/L in H9c2 cells (Lo et al. 2005). A concentration of 100 µmol/L was needed to 
fully block IKs in these cells. This correspond well to the relaxation-prolonging effect in 
FBMEs, which was visible at 10 µmol/L and marked at 100 µmol/L (Figure 10) matching 
quite well the published data (Lo et al. 2005). Quinidine, known as a class IA antiarrhythmic 
drug according to Vaughan-Williams classification (Vaughan-Williams 1975), also blocks IKs 
and IKr with EC50 values of 10 µmol/L and 300 nmol/L, respectively (Lo et al. 2005; Redfern 
et al. 2003). In FBMEs, quinidine prolonged relaxation time at 100 µmol/L. This is not an 
entirely different range in comparison with the determined IC50 for quinidine on IKs but far 
away from IKr-IC50. This argues again for the role of IKs in FBME-repolarisation. 
Erythromycin, a clinically used antibiotic, which is associated with Torsades-de-Pointes 
arrhythmias and increased lethality in men (Ray et al. 2004), inhibits IKr but not IKs in dogs 
(Antzelevitch et al. 1996) and increases action potential duration in rat ventricular 
cardiomyocytes (IC50 60 µmol/L; Hanada et al. 2003). In FBMEs erythromycin caused an 
increase in relaxation time at concentrations of 100 µmol/L and above. Even though the 
channel subunits for both IKr and IKs are expressed on mRNA-level in FBMEs (Figure 7), 
their role in repolarisation of rat cardiomyocytes is still controversial (Regan et al. 2005). In 
any case, the observation that the prototype proarrhythmic drugs specifically affected 
relaxation time in FBMEs indicates that this parameter may be useful as a surrogate of 
repolarisation. However, the detailed mechanisms behind the cardiotoxic and 
proarrhythmic effects are still unclear and need to be further investigated in follow up 
studies.  
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The presented technique still has a number of important limitations with regard to drug 
screening. (i) The cell preparation cannot be fully standardized. In particular, the age of 
newborn rats varies from 0-3 days and has significant impact of the quality of FBMEs, most 
likely explaining part of the variability between series (Figure 6). (ii) The system is not well 
suited to determine acute positive or negative inotropic effects because measurements are 
done under spontaneous beating, leading to confounding effects of concomitant negative or 
positive chronotropic effects. We are working on a system which allows measurements to be 
done under continuous pacing. (iii) Histological observations showed spindle-shaped 
cardiomyocytes and a predominantly lateral orientation of connexion-43-postive gap 
junctions. This suggests that cardiomyocytes, despite functional, molecular and 
morphological indices of advanced maturation, do not reach an adult phenotype. (iv) Our 
assay system exclusively monitors alterations in contractile activity and does not directly 
determine calcium transients or action potential duration. We believe that relaxation time is 
a good surrogate parameter of action potential, but the direct proof is still lacking. (v) 
Finally, rodents are known to be poor models for detecting proarrhythmic drug effects 
because mechanisms governing their action potential differ considerably from that in 
humans. For example, IKr plays a relatively minor role in rodents, but a major one in humans 
(Regan et al. 2005). Our present results suggest that proarrhythmic drug effects can still be 
monitored in this system, but much more work is necessary to determine which ion channel 
or combination of ion channels have to be blocked to see changes in relaxation time and/or 
arrhythmias in FBMEs.  
Thus, validation of the new system will require testing of a large number of drugs that are 
known to cause cardiac arrhythmias in humans and those that are known to be free of 
arrhythmic side effects, including those that have effects on HERG but are not associated 
with Torsades-de-Pointes arrhythmias. Moreover, a number of randomly chosen new 
chemical entities should be analysed to obtain an estimate how many non selected 
compounds give a signal. These studies are currently under way. 
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